Skip to main content

Table 2 Descriptive characteristics of patients enrolled in the study (n = 20)

From: A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients

Patient characteristic No.
Age, median (range) 47 years (36–62)
Tumor size, median (range) 20 mm (5–40)
Histopathology
 Ductal carcinoma in situ (DCIS) 4 (20 %)
 Invasive ductal carcinoma 15 (75 %)
 Invasive lobular carcinoma 1 (5 %)
Axillary involvement in invasive carcinoma, n = 16 7 (43 %)
Molecular subtype of invasive carcinoma, n = 16
 Luminal (A and B) 11 (69 %)
 Her2 1 (6 %)
 Triple negative 4 (25 %)
V2R status known, n = 18
 Positive tumor expression 6 (33 %)
Type of surgery
 Breast conserving surgery 12 (60 %)
 Mastectomy 8 (40 %)
Postoperative adjuvant therapy
 None (DCIS) 4 (20 %)
 Cyclophosphamide-based chemotherapy 6 (30 %)
 Radiotherapy 3 (15 %)
 Chemoradiotherapy 7 (35 %)